Active Biotech AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
115,970.00
10,399.00
16,275.00
19,042.00
5,206.00
20,051
SG&A Expense
312,102.00
226,603.00
185,014.00
65,256.00
63,390.00
49,407
EBIT
209,025.00
228,460.00
177,927.00
55,124.00
64,318.00
29,803
Unusual Expense
9,392.00
6,684.00
111.00
159.00
49,986.00
96
Non Operating Income/Expense
1,220.00
340.00
155.00
291.00
11,547.00
9
Interest Expense
13,645.00
11,704.00
6,867.00
7,126.00
7,140.00
6,970
Pretax Income
214,294.00
233,720.00
184,739.00
61,792.00
109,897.00
36,878
Income Tax
2,208.00
2,208.00
8,792.00
2,208.00
1,104.00
-
Consolidated Net Income
212,086.00
231,512.00
193,531.00
59,584.00
108,793.00
36,878
Net Income
212,086.00
231,512.00
193,531.00
59,584.00
108,793.00
36,878
Net Income After Extraordinaries
212,086.00
231,512.00
193,531.00
59,584.00
108,793.00
36,878
Net Income Available to Common
212,086.00
231,512.00
193,531.00
59,584.00
108,793.00
36,878
EPS (Basic)
2.00
2.23
1.59
0.49
0.84
0.27
Basic Shares Outstanding
105,998.40
103,847.00
121,643.60
121,113.70
128,806.60
137,492.40
EPS (Diluted)
2.00
2.23
1.59
0.49
0.84
0.27
Diluted Shares Outstanding
105,998.40
103,847.00
121,643.60
121,113.70
128,806.60
137,492.40
EBITDA
196,132.00
216,204.00
168,739.00
46,214.00
58,184.00
29,356
Non-Operating Interest Income
204.00
100.00
11.00
8.00
-
-

About Active Biotech AB

View Profile
Address
Scheelevägen 22
Lund SN 223 63
Sweden
Employees -
Website http://www.activebiotech.com
Updated 07/08/2019
Active Biotech AB develops pharmaceutical preparations. It develops pharmaceutical products within medical areas where the immune defense is of significant importance, including neurodegenerative diseases, autoimmune, inflammatory disease and various forms of cancer. The company's project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy.